Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial - PubMed
8 hours ago
- #Clinical Trial
- #Chronic Lymphocytic Leukemia
- #Venetoclax
- The CLL13/GAIA trial compared fixed-duration venetoclax combinations (RV, GV, GIV) against chemoimmunotherapy (CIT) in untreated, fit CLL patients without TP53 aberrations.
- After a median follow-up of 63.8 months, the 5-year progression-free survival (PFS) rates were highest with GIV (81.3%), followed by GV (69.8%), RV (57.4%), and CIT (50.7%). GIV and GV showed superior PFS compared to CIT and RV.
- Patient-reported outcomes indicated rapid and significant quality of life (QoL) improvements with GV and RV, whereas GIV had a delayed improvement due to higher symptom burden.
- Overall survival did not differ significantly between treatment arms, and venetoclax-based retreatment after first-line therapy was efficacious.
- Severe infections were most common with CIT, while cardiac events were most frequent with GIV.